MARKET

PROK

PROK

ProKidney
NASDAQ
1.990
+0.120
+6.42%
After Hours: 2.020 +0.03 +1.51% 19:08 02/09 EST
OPEN
1.890
PREV CLOSE
1.870
HIGH
2.020
LOW
1.795
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
7.13
52 WEEK LOW
0.4603
MARKET CAP
598.66M
P/E (TTM)
-3.6561
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PROK last week (0202-0206)?
Weekly Report · 21h ago
Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
TipRanks · 6d ago
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
TipRanks · 02/03 02:46
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
TipRanks · 02/02 21:40
Prokidney Updates Phase 3 REGEN-006 Trial Enrollment Of ~470 Subjects
Benzinga · 02/02 21:09
PROKIDNEY CORP - TOPLINE DATA READOUT OF SURROGATE ENDPOINT EXPECTED Q2 2027 - SEC FILING
Reuters · 02/02 21:06
PROKIDNEY CORP - UPDATES PHASE 3 STUDY ENROLLMENT TO 470 SUBJECTS - SEC FILING
Reuters · 02/02 21:06
Weekly Report: what happened at PROK last week (0126-0130)?
Weekly Report · 02/02 10:34
More
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Webull offers ProKidney Corp stock information, including NASDAQ: PROK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROK stock methods without spending real money on the virtual paper trading platform.